

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

All items marked with an * are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name Nucleix * Website <https://nucleix.com/> *

CEO name Chris Hibberd *

Select a CATEGORY: Biotech *

(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *

(Delete sessions you are not selecting)

4. Can we Successfully Diagnose and Guide Patients' Optimal Cancer Treatment?

You may delete the section instructions, leaving **only the bolded bullet title**

Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational**
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients.
- **Core Technology**
Leveraging NGS and PCR-based technologies, the Company's pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. Recently the company announced great advancements in early lung cancer detection arising from an extensive proprietary lung ATLAS program, which leverages a powerful EpiCheck NGS discovery technology. The Company's non-invasive EpiCheck® delivers highly accurate and sensitive results, while providing a seamless testing option for physicians, patients, and the healthcare system.
- **Product Profile/Pipeline**
The Company is building an EpiCheck® franchise in lung cancer and in bladder cancer. In bladder cancer the Bladder EpiCheck® kit is CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer. The Company is also advancing its Lung EpiCheck®, a screening test for high-risk individuals, with a large multicenter study in the US of.
- **Business Strategy**
Briefly describe how the company will apply its core technology, generate short-term and long-term revenues. The company is selling the Bladder EpiCheck® kit in Europe and is currently awaiting FDA 510K clearance in the USA. The company is also advancing a Lung EpiCheck® test via its San Diego based CLIA-certified CAP accredited lab.
- **What's Next?**
Nucleix is running the Sightline study in the US to define and validate Lung EpiCheck®. Sightline is a multicenter study enrolling 5,000 high-risk smokers and primary lung cancer. Nucleix plans to launch new bladder and lung products and the company is

continuing to leverage and advance the EpiCheck[®] NGS platform which demonstrated extraordinary results from the lung ATLAS initiative.